Morgan Stanley Galecto, Inc. Call Options Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GLTO
# of Institutions
1Shares Held
21.2KCall Options Held
0Put Options Held
0About Galecto, Inc.
- Ticker GLTO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,395,700
- Market Cap $119M
- Description
- Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...